



NEWS RELEASE

ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index

12/16/2021

ATLANTA & NEW YORK--(BUSINESS WIRE)-- Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of data, technology and market infrastructure, today announced the annual reconstitution of the ICE Biotechnology Index (ICEBIO), which is effective before the open of trading on Monday, December 20, 2021.

The ICE Biotechnology Index tracks the performance of qualifying U.S. listed biotechnology companies classified within the Biotechnology Sub-Industry Group of the ICE Uniform Sector Classification schema, which is a multi-asset class industry classification taxonomy developed by ICE. The index includes companies that are engaged in the research and development of therapeutic treatments but are not focused on the commercialization and mass production of pharmaceutical drugs. The index also includes companies that are engaged in the production of tools or systems that enable biotechnology processes.

“This annual reconstitution ensures that the index maintains its representation of the broader biotechnology industry,” said Aram Flores, Head of Index and Analytics at ICE. “By including companies meeting a minimum threshold of market capitalization and liquidity from multiple U.S. exchanges, the index provides a better gauge of the biotechnology industry and helps improve the investability for users benchmarking to the index.”

The following companies will be added to and removed from the index in the December 2021 annual reconstitution:

Ticker	Name	Action
ABCL	AbCellera Biologics, Inc.	Addition



ABCM	Abcam PLC Sponsored ADR	Addition
ABOS	Acumen Pharmaceuticals, Inc.	Addition
ABSI	Absci Corporation	Addition
ACET	Adicet Bio Inc	Addition
ACHL	Achilles Therapeutics PLC Sponsored ADR	Addition
ACRS	Aclaris Therapeutics, Inc.	Addition
ADMA	ADMA Biologics, Inc.	Addition
AKUS	Akouos, Inc.	Addition
AKYA	Akoya Biosciences Inc	Addition
ALGS	Aligos Therapeutics, Inc.	Addition
ALPN	Alpine Immune Sciences, Inc.	Addition
ALVR	AlloVir Inc	Addition
AMPE	Ampio Pharmaceuticals, Inc.	Addition
ANVS	Annovis Bio Inc	Addition
ATAI	ATAI Life Sciences N.V.	Addition
ATHA	Athira Pharma, Inc.	Addition
AUPH	Aurinia Pharmaceuticals Inc.	Addition
AUTL	Autolus Therapeutics Plc Sponsored ADR	Addition
AVIR	Atea Pharmaceuticals, Inc.	Addition
AVTE	Aerovate Therapeutics, Inc.	Addition
AVXL	Anavex Life Sciences Corp.	Addition
BCAB	BioAtla, Inc.	Addition
BCYC	Bicycle Therapeutics Plc Sponsored ADR	Addition
BLU	BELLUS Health Inc.	Addition
BMEA	Biomea Fusion Inc	Addition
BNR	Burning Rock Biotech Ltd. Sponsored ADR Class A	Addition
BOLT	Bolt Biotherapeutics, Inc.	Addition
BTX	Brooklyn ImmunoTherapeutics, Inc.	Addition
CADL	Candel Therapeutics, Inc.	Addition
CCCC	C4 Therapeutics, Inc.	Addition
CDAK	Codiak BioSciences, Inc.	Addition
CGEM	Cullinan Oncology, Inc.	Addition
CLSD	Clearside Biomedical, Inc.	Addition
CMPS	COMPASS Pathways Plc Sponsored ADR	Addition
CMRX	Chimerix, Inc.	Addition
CNTA	Centessa Pharmaceuticals PLC ADR	Addition
CNTB	Connect Biopharma Holdings Ltd. Sponsored ADR	Addition
CRBU	Caribou Biosciences, Inc.	Addition
CRIS	Curis, Inc.	Addition
CTKB	Cytek Biosciences, Inc.	Addition
CVAC	CureVac N.V.	Addition
CYBN	Cybin, Inc.	Addition
CYT	Cyteir Therapeutics, Inc.	Addition
DAWN	Day One Biopharmaceuticals, Inc.	Addition
DBTX	Decibel Therapeutics, Inc.	Addition
DBVT	DBV Technologies SA Sponsored ADR	Addition
DNAY	Codex DNA, Inc.	Addition
DSGN	Design Therapeutics, Inc.	Addition
DYN	Dyne Therapeutics Inc	Addition
ERAS	Erasca, Inc.	Addition
ETNB	89bio Inc	Addition
EVLO	Evelo Biosciences, Inc.	Addition
EWTX	Edgewise Therapeutics, Inc.	Addition
FDMT	4D Molecular Therapeutics, Inc.	Addition
GLUE	Monte Rosa Therapeutics, Inc.	Addition
GRCL	Gracell Biotechnologies Inc. Sponsored ADR Class A	Addition
GRPH	Graphite Bio, Inc.	Addition
GRTS	Gritstone bio, Inc.	Addition
GTH	Genetron Holdings Ltd Sponsored ADR	Addition
HBIO	Harvard Bioscience, Inc.	Addition
HOWL	Werewolf Therapeutics, Inc.	Addition
HUMA	Humacyte, Inc.	Addition
ICVX	Icosavax, Inc.	Addition
IKNA	Ikena Oncology, Inc.	Addition
IMGO	Imago BioSciences, Inc.	Addition
IMMP	Immutep Ltd Sponsored ADR	Addition
IMPL	Impel NeuroPharma, Inc.	Addition
IMRX	Immuneering Corp. Class A	Addition
INBX	inhibrx Inc	Addition
INFI	Infinity Pharmaceuticals, Inc.	Addition
IPHA	Innate Pharma SA Sponsored ADR	Addition
IPSC	Century Therapeutics, Inc.	Addition
IANX	Ianux Therapeutics, Inc.	Addition
KMDA	Kamada Ltd	Addition
KMPH	KemPharm, Inc.	Addition
KNTE	Kinnate Biopharma, Inc.	Addition
KRON	Kronos Bio Inc	Addition
KYMR	Kymera Therapeutics, Inc.	Addition

LABP	Landos Biopharma, Inc.	Addition
LCTX	Lineage Cell Therapeutics, Inc.	Addition
LPTX	Leap Therapeutics, Inc.	Addition
LYEL	Lyell Immunopharma, Inc.	Addition
MBIO	Mustang Bio, Inc.	Addition
MIRM	Mirum Pharmaceuticals, Inc.	Addition
MORF	Morphic Holding, Inc.	Addition
MREO	Mereo BioPharma Group plc Sponsored ADR	Addition
MRUS	Merus N.V.	Addition
MRVI	Maravai LifeSciences Holdings Inc Class A	Addition
MTEM	Molecular Templates, Inc.	Addition
MTNB	Matinas BioPharma Holdings, Inc.	Addition
MXCT	MaxCyte, Inc.	Addition
NAUT	Nautilus Biotechnology, Inc.	Addition
NRXP	NRX Pharmaceuticals, Inc.	Addition
NUVB	Nuvation Bio Inc Class A	Addition
NUVL	Nuvalent, Inc. Class A	Addition
OBSV	ObsEva SA	Addition
OCCX	Oncocyte Corporation	Addition
OLK	Olink Holding AB Sponsored ADR	Addition
OLMA	Olema Pharmaceuticals, Inc.	Addition
OMGA	Omega Therapeutics, Inc.	Addition
OMIC	Singular Genomics Systems, Inc.	Addition
ONCR	Oncorus, Inc.	Addition
OYST	Oyster Point Pharma Inc	Addition
PCVX	Vaxcyte, Inc.	Addition
PHAT	Phathom Pharmaceuticals, Inc.	Addition
PMVP	PMV Pharmaceuticals, Inc.	Addition
PRAX	Praxis Precision Medicines, Inc.	Addition
PRLD	Prelude Therapeutics, Inc.	Addition
PRQR	ProQR Therapeutics N.V.	Addition
RAIN	Rain Therapeutics Inc	Addition
RANI	Rani Therapeutics Holdings, Inc. Class A	Addition
RLYB	Rallybio Corporation	Addition
ROIV	Roivant Sciences Ltd.	Addition
RXDX	Prometheus Biosciences, Inc.	Addition
RXXR	Recursion Pharmaceuticals, Inc Class A	Addition
SANA	Sana Biotechnology, Inc.	Addition
SBTX	Silverback Therapeutics, Inc.	Addition
SEER	Seer, Inc. Class A	Addition
SESN	Sesen Bio, Inc.	Addition
SLDB	Solid Biosciences Inc.	Addition
SMMT	Summit Therapeutics Inc	Addition
SNSE	Sensei Biotherapeutics, Inc.	Addition
SOZ	SOZ Biotechnologies Company	Addition
STTK	Shattuck Labs, Inc.	Addition
STVN	Stevanato Group SpA	Addition
SYNH	Syneos Health, Inc. Class A	Addition
TALS	Talaris Therapeutics, Inc.	Addition
TERN	Terns Pharmaceuticals, Inc.	Addition
TIL	Instil Bio, Inc.	Addition
TKNO	Alpha Teknova, Inc.	Addition
TNYA	Tenaya Therapeutics, Inc.	Addition
TSHA	Taysha Gene Therapies, Inc.	Addition
VERV	Verve Therapeutics, Inc.	Addition
MIRX	Viracta Therapeutics, Inc.	Addition
VOR	Vor Biopharma, Inc.	Addition
VRCA	Verrica Pharmaceuticals Inc.	Addition
AMRS	Amyris, Inc.	Deletion
APRE	Aprea Therapeutics, Inc.	Deletion
ARDX	Ardelyx, Inc.	Deletion
ASMB	Assembly Biosciences, Inc.	Deletion
BCEL	Atreca, Inc. Class A	Deletion
CALA	Calithera Biosciences, Inc.	Deletion
CERS	Cerus Corporation	Deletion
CNCE	Concert Pharmaceuticals, Inc.	Deletion
EGRX	Eagle Pharmaceuticals, Inc.	Deletion
ESPR	Esperion Therapeutics, Inc.	Deletion
GH	Guardant Health, Inc.	Deletion
INZY	Inozyme Pharma, Inc.	Deletion
KALA	Kala Pharmaceuticals, Inc.	Deletion
KLDO	Kaleido Biosciences, Inc.	Deletion
MNOV	MediciNova, Inc.	Deletion
MOR	MorphoSys AG Sponsored ADR	Deletion
NCNA	NuCana plc Sponsored ADR	Deletion
ODT	Odonate Therapeutics, Inc.	Deletion
OMER	Omeros Corporation	Deletion
SIGA	SIGA Technologies Inc	Deletion



SUPN	Supernus Pharmaceuticals, Inc.	Deletion
TLSA	Tiziana Life Sciences Ltd.	Deletion
UBX	Unity Biotechnology, Inc.	Deletion
VRNA	Verona Pharma plc Sponsored ADR	Deletion
YGR	Voyager Therapeutics, Inc.	Deletion
XBIT	XBiotech, Inc.	Deletion

ICE's global family of indices serve as the performance benchmark for more than \$1 trillion in assets managed by investors around the globe. For more information about ICE's Indices, please visit: <https://www.ice.com/market-data/indices>.

About Intercontinental Exchange

Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds and operates digital networks to connect people to opportunity. We provide financial technology and data services across major asset classes that offer our customers access to mission-critical workflow tools that increase transparency and operational efficiencies. We operate **exchanges**, including the **New York Stock Exchange**, and **clearing houses** that help people invest, raise capital and manage risk across multiple asset classes. Our comprehensive fixed income **data services** and execution capabilities provide information, analytics and platforms that help our customers capitalize on opportunities and operate more efficiently. At **ICE Mortgage Technology**, we are transforming and digitizing the U.S. residential mortgage process, from consumer engagement through loan registration. Together, we transform, streamline and automate industries to connect our customers to opportunity.

Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange. Information regarding additional trademarks and intellectual property rights of Intercontinental Exchange, Inc. and/or its affiliates is located **here**. Key Information Documents for certain products covered by the EU Packaged Retail and Insurance-based Investment Products Regulation can be accessed on the relevant exchange website under the heading "Key Information Documents (KIDS)."

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 -- Statements in this press release regarding ICE's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE's Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE's Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on February 4, 2021.

SOURCE: Intercontinental Exchange

ICE-CORP

ICE Media Contact:

Damon Leavell

damon.leavell@ice.com

(212) 323-8587

media@ice.com

ICE Investor Contact:

Mary Caroline O'Neal

marycaroline.oneal@ice.com

(770) 738-2151

investors@ice.com

Source: Intercontinental Exchange